Evaluation of antitumor potential of synthesized novel 2-substituted 4-anilinoquinazolines as quinazoline-pyrrole hybrids in MCF-7 human breast cancer cell line and A-549 human lung adenocarcinoma cell lines

Future Journal of Pharmaceutical Sciences

Table 3 Anticancer activity of targeted quinazoline derivatives

Compound code	24 h	48 h	72 h
IC 50 (μM) of A-549 human adenocarcinoma cells
7d	49.93 ± 2.23	43.99 ± 1.56	41.05 ± 0.59
7f	49.94 ± 4.56	49.28 ± 2.54	45.54 ± 1.26
7 g	54.65 ± 3.06	50.55 ± 3.54	46.93 ± 1.69
7 h	60.62 ± 2.58	59.09 ± 1.26	48.62 ± 0.93
Doxorubicin	52.37 ± 3.69	49.13 ± 2.9	48.62 ± 2.56
IC 50 (μM) of MCF-7 human breast cancer cells
7d	43.99 ± 1.65	41.56 ± 1.43	40.64 ± 0.89
7f	47.70 ± 3.68	46.37 ± 1.88	44.98 ± 1.96
Doxorubicin	54.29 ± 2.46	50.67 ± 1.03	47.62 ± 2.56